ABSTRACT
In each of three trials, 240 crossbred barrows weaned at 17 d of age (5.1 kg BW) were assigned to one of three experimental treatments based on light and heavy weight outcome groups. Experimental treatments were 1) wean-to-finish at 0.69 m2/pig and 15 pigs/pen; 2) wean-to-finish double-stocked at 0.35 m2/pig, 30 pigs per pen for 8 wk and then randomly split into two pens (either stayed in same pen or moved to new pen) for growth to slaughter at 0.69 m2/pig; and 3) nursery facility for 8 wk at 0.35 m2/pig and 15 pigs/pen followed by move to the same grow-finish facility housing wean-to-finish and double-stocked pigs and maintaining pen integrity. Beginning at 38 kg BW, diets were supplemented with either bacitracin methylenedisalicylate at 33 mg/kg to slaughter or tylosin at 44 mg/kg to 59 kg BW and 22 mg/kg thereafter. There were no trial x treatment interactions, even though there was considerable variation in health status among trials. At the end of the 56-d nursery period, wean-to-finish pigs weighed more than nursery (28.7 vs 27.7 kg; P = 0.071) and double-stocked pigs (28.7 vs 26.9 kg; P = 0.002), due to greater ADG (wean-to-finish vs nursery; P = 0.062; wean-to-finish vs double-stocked; P = 0.002) and greater ADFI (wean-to-finish vs nursery; P = 0.024; wean-to-finish vs double-stocked, P = 0.002). There was no effect of treatments (P > 0.1) on ADG, feed conversion, carcass lean percentage, or lean gain during the growing-finishing period. There was also no effect of treatment (P > 0.1) on ADG or ADFI from weaning to slaughter. There was no difference (P > 0.1) between bacitracin methylenedisalicylate and tylosin for ADG, feed conversion, carcass lean percentage, or daily lean gain. These data suggest that housing 5-kg weaned pigs in fully slatted growing-finishing facilities from weaning to slaughter was not detrimental to overall performance. In this experiment, dietary additions of bacitracin methylenedisalicylate or tylosin from 38 kg BW to slaughter weight resulted in similar growth performance.
